Lung Cancer
A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
NCI-04-C-0049
Print this page 
Investigator(s): |
John C. Morris, M.D.
Principal Investigator
Phone: 301-402-2912
jmorris@mail.nih.gov
|
|
|
|
Nancy Harold, R.N.
Research Nurse
Phone: 301-435-5612
Fax: 301-480-2590
haroldn@mail.nih.gov
|
|
|
| |
Primary Eligibility:
- Non-small cell lung cancer (adenocarcinoma, bronchoalveolar carcinoma, large cell anaplastic carcinoma or squamous cell carcinoma)
- Stage IV, recurrent or treatment refractory non-small cell lung cancer (NSCLC)
- Measurable disease
- Must have a granulocyte count of ≥ 1500/mm³, lymphocyte count of ≥ 475/mm³, platelets ≥ 100,000/mm³, hemoglobin > 10.0 gm/dL, albumin ≥ 3.0 gm/dL and acceptable hepatic and renal function
- Not receiving systemic corticosteroid therapy
Study Outline:
- Patients will be intradermally vaccinated with irradiated Alpha (1,3) galactosyltransferase-expressing lung cancer vaccine cells every 2 weeks to complete a total of eight vaccinations
Additional Information:
- This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
- There is no charge for medical care received at NIH Clinical Center.
- FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
- PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
Reviewed: 9/8/09
Updated: 10/7/09
Back to Top
